I'm confused...this seems to be another study The study was conducted by an independent Contract Research Organisation to assess the in-vitro efficacy of R327 against all ESKAPE pathogen bacterial strains. R327 is a broad-spectrum synthetic
anti-infective that has potential to address the urgent global health threat posed by antibiotic resistant
superbugs and emerging viral pathogens.
So it's not ferrets etc. But no matter. It's all GOOD!!
- Forums
- ASX - By Stock
- Ann: Positive Data on RECCE 327 Against All Six ESKAPE Pathogens
RCE
recce pharmaceuticals ltd
Add to My Watchlist
1.69%
!
29.0¢

I'm confused...this seems to be another study The study was...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $83.62M |
Open | High | Low | Value | Volume |
29.0¢ | 30.0¢ | 28.5¢ | $37.25K | 127.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 161128 | 28.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 9666 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 161128 | 0.285 |
10 | 343798 | 0.280 |
4 | 37019 | 0.275 |
4 | 24814 | 0.270 |
1 | 5000 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 9666 | 1 |
0.330 | 114230 | 1 |
0.350 | 31739 | 3 |
0.375 | 8002 | 1 |
0.380 | 6820 | 2 |
Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |